# Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)

> **NCT01968213** · PHASE3 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 564 (actual)

## Conditions studied

- Ovarian Cancer
- Fallopian Tube Cancer
- Peritoneal Cancer

## Interventions

- **DRUG:** Rucaparib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01968213
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04-07
- **Primary completion:** 2017-04-01
- **Final completion:** 2022-07-07
- **Target enrollment:** 564 (ACTUAL)
- **Last updated:** 2023-06-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01968213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01968213, "Phase 3 Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous or Endometrioid Ovarian Cancer (ARIEL3)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01968213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*